Weighing bone-targeted treatment options for patients with solid tumours and skeletal complications from metastatic disease

Lesley Fallowfield, Roger von Moos, Luis Costa, Alison T Stopeck, Mark Clemons, Noel Clarke, Ada Braun, Karen Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The complications of metastatic bone disease (MBD) in advanced cancer, especially skeletal-related events (SREs), are a significant cause of morbidity that can seriously impair the quality of patients' lives. Treatments that prevent SREs, reduce or delay the onset of pain and preserve function and activities of daily living are central to good patient care. In this article, we discuss results from clinical trials that show the relative benefits and harms of different bone-targeted agents, which may be given orally, intravenously or subcutaneously. These data, when considered alongside various patient characteristics, can provide oncologists with better opportunities to individualise care. Optimal management with treatments that enhance efficacy and adherence mean that clinicians can improve the outlook for their patients with MBD, who may consequently experience fewer SREs and less pain and enjoy a better overall quality of life.

Original languageEnglish (US)
Pages (from-to)148-155
Number of pages8
JournalEuropean Oncology and Haematology
Volume8
Issue number3
StatePublished - Jul 2012

Fingerprint

Bone Diseases
Bone and Bones
Pain
Neoplasms
Activities of Daily Living
Patient Care
Therapeutics
Quality of Life
Clinical Trials
Morbidity
Oncologists

Keywords

  • Advanced cancer
  • Bisphosphonates
  • Bone metastases
  • Bone resorption
  • Clinical trials
  • Denosumab
  • Metastatic bone disease
  • Osteoclast
  • RANK ligand

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Weighing bone-targeted treatment options for patients with solid tumours and skeletal complications from metastatic disease. / Fallowfield, Lesley; von Moos, Roger; Costa, Luis; Stopeck, Alison T; Clemons, Mark; Clarke, Noel; Braun, Ada; Chung, Karen.

In: European Oncology and Haematology, Vol. 8, No. 3, 07.2012, p. 148-155.

Research output: Contribution to journalArticle

Fallowfield, L, von Moos, R, Costa, L, Stopeck, AT, Clemons, M, Clarke, N, Braun, A & Chung, K 2012, 'Weighing bone-targeted treatment options for patients with solid tumours and skeletal complications from metastatic disease', European Oncology and Haematology, vol. 8, no. 3, pp. 148-155.
Fallowfield, Lesley ; von Moos, Roger ; Costa, Luis ; Stopeck, Alison T ; Clemons, Mark ; Clarke, Noel ; Braun, Ada ; Chung, Karen. / Weighing bone-targeted treatment options for patients with solid tumours and skeletal complications from metastatic disease. In: European Oncology and Haematology. 2012 ; Vol. 8, No. 3. pp. 148-155.
@article{a9ae34d07c864529a1addc623441ae5f,
title = "Weighing bone-targeted treatment options for patients with solid tumours and skeletal complications from metastatic disease",
abstract = "The complications of metastatic bone disease (MBD) in advanced cancer, especially skeletal-related events (SREs), are a significant cause of morbidity that can seriously impair the quality of patients' lives. Treatments that prevent SREs, reduce or delay the onset of pain and preserve function and activities of daily living are central to good patient care. In this article, we discuss results from clinical trials that show the relative benefits and harms of different bone-targeted agents, which may be given orally, intravenously or subcutaneously. These data, when considered alongside various patient characteristics, can provide oncologists with better opportunities to individualise care. Optimal management with treatments that enhance efficacy and adherence mean that clinicians can improve the outlook for their patients with MBD, who may consequently experience fewer SREs and less pain and enjoy a better overall quality of life.",
keywords = "Advanced cancer, Bisphosphonates, Bone metastases, Bone resorption, Clinical trials, Denosumab, Metastatic bone disease, Osteoclast, RANK ligand",
author = "Lesley Fallowfield and {von Moos}, Roger and Luis Costa and Stopeck, {Alison T} and Mark Clemons and Noel Clarke and Ada Braun and Karen Chung",
year = "2012",
month = "7",
language = "English (US)",
volume = "8",
pages = "148--155",
journal = "European Oncology and Haematology",
issn = "2045-5275",
publisher = "Touch Digital Media",
number = "3",

}

TY - JOUR

T1 - Weighing bone-targeted treatment options for patients with solid tumours and skeletal complications from metastatic disease

AU - Fallowfield, Lesley

AU - von Moos, Roger

AU - Costa, Luis

AU - Stopeck, Alison T

AU - Clemons, Mark

AU - Clarke, Noel

AU - Braun, Ada

AU - Chung, Karen

PY - 2012/7

Y1 - 2012/7

N2 - The complications of metastatic bone disease (MBD) in advanced cancer, especially skeletal-related events (SREs), are a significant cause of morbidity that can seriously impair the quality of patients' lives. Treatments that prevent SREs, reduce or delay the onset of pain and preserve function and activities of daily living are central to good patient care. In this article, we discuss results from clinical trials that show the relative benefits and harms of different bone-targeted agents, which may be given orally, intravenously or subcutaneously. These data, when considered alongside various patient characteristics, can provide oncologists with better opportunities to individualise care. Optimal management with treatments that enhance efficacy and adherence mean that clinicians can improve the outlook for their patients with MBD, who may consequently experience fewer SREs and less pain and enjoy a better overall quality of life.

AB - The complications of metastatic bone disease (MBD) in advanced cancer, especially skeletal-related events (SREs), are a significant cause of morbidity that can seriously impair the quality of patients' lives. Treatments that prevent SREs, reduce or delay the onset of pain and preserve function and activities of daily living are central to good patient care. In this article, we discuss results from clinical trials that show the relative benefits and harms of different bone-targeted agents, which may be given orally, intravenously or subcutaneously. These data, when considered alongside various patient characteristics, can provide oncologists with better opportunities to individualise care. Optimal management with treatments that enhance efficacy and adherence mean that clinicians can improve the outlook for their patients with MBD, who may consequently experience fewer SREs and less pain and enjoy a better overall quality of life.

KW - Advanced cancer

KW - Bisphosphonates

KW - Bone metastases

KW - Bone resorption

KW - Clinical trials

KW - Denosumab

KW - Metastatic bone disease

KW - Osteoclast

KW - RANK ligand

UR - http://www.scopus.com/inward/record.url?scp=84873260320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873260320&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84873260320

VL - 8

SP - 148

EP - 155

JO - European Oncology and Haematology

JF - European Oncology and Haematology

SN - 2045-5275

IS - 3

ER -